CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

- a) a guide for reporting for authors of RCTs,
- b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form OGNSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions J_Med Internet Res 2011;13(4):e126 URL: http://www.jmir.org/2011/4/e126/ (iii): 10.2196/jmir.1923 1 1D: 22209829 chuajingshi@gmail.com (not shared) Switch account Draft saved * Required 11. Your name * First Last (!) Jing Shi Chua Primary Affiliation (short), City, Country * University of Toronto, Toronto, Canada National University of Singapore, Singapore Your e-mail address * abc@gmail.com jingshi@nus.edu.sg \Rightarrow Title of your manuscript * Provide the (draft) title of your manuscript.

Exaluating the effectiveness of the Supportive Parenting App (SPA) on parental outcomes: A randomized controlled trial

Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

Supportive Parenting App

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Your answer

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

Your answer

URL of an image/screenshot (optional)

Your answer

| Accessibility * Can an enduser access the intervention presently? |
|---|
| access is free and open |
| access only for special usergroups, not open |
| access is open to everyone, but requires payment/subscription/in-app purchases |
| app/intervention no longer accessible |
| Other: |
| |
| Primary Medical Indication/Disease/Condition * e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)" |
| |
| Postnatal depression |
| Primary Outcomes measured in trial * |
| |
| Primary Outcomes measured in trial * comma-separated list of primary outcomes reported in the trial |
| Primary Outcomes measured in trial * comma-separated list of primary outcomes reported in the trial Postnatal depression, anxiety, parental bonding Secondary/other outcomes |
| Primary Outcomes measured in trial * comma-separated list of primary outcomes reported in the trial Postnatal depression, anxiety, parental bonding |

| Recommended "Dose" * What do the instructions for users say on how often the app should be used? |
|--|
| Approximately Daily |
| Approximately Weekly |
| Approximately Monthly |
| Approximately Yearly |
| as needed" |
| Other: |
| |
| Approx. Percentage of Users (starters) still using the app as recommended after * 3 months |
| unknown / not evaluated |
| O-10% |
| O 11-20% |
| 21-30% |
| 31-40% |
| O 41-50% |
| S1-60 % |
| O 61-70% |
| 1 71%-80% |
| 81-90% |
| 91-100% |
| O 31 100% |

!

| Overall, was the app/intervention effective? * |
|---|
| yes: all primary outcomes were significantly better in intervention group vs control |
| partly: SOME primary outcomes were significantly better in intervention group vs control |
| on statistically significant difference between control and intervention |
| outcomes potentially harmful: control was significantly better than intervention in one or more |
| inconclusive: more research is needed |
| Other: |
| |
| |
| Article Preparation Status/Stage * |
| Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) |
| • |
| At which stage in your article preparation are you currently (at the time you fill in this form) |
| At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status |
| At which stage in your article preparation are you currently (at the time you fill in this form) one of submitted yet - in early draft status not submitted yet - in late draft status, just before submission |
| At which stage in your article preparation are you currently (at the time you fill in this form) one of submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet |
| At which stage in your article preparation are you currently (at the time you fill in this form) onot submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments |
| At which stage in your article preparation are you currently (at the time you fill in this form) onot submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments submitted to a journal and accepted, but not published yet |

| Journal * If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other") |
|--|
| onot submitted yet / unclear where I will submit this |
| Journal of Medical Internet Research (JMIR) |
| JMIR mHealth and UHealth |
| JMIR Serious Games |
| JMIR Mental Health |
| JMIR Public Health |
| JMIR Formative Research |
| Other JMIR sister journal |
| Other: |
| |
| Is this a full powered effectiveness trial or a pilot/feasibility trial? * |
| O Pilot/feasibility |
| Fully powered |
| |
| Manuscript tracking number * If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR) |
| on ms number (yet) / not (yet) submitted to / published in JMIR |

!

Other: ms#41859

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

yes

Other:

1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

subitem not at all important

essential

Does your paper address subitem 1a-i? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Evaluating the effectiveness of the Supportive Parenting App (SPA) on parental outcomes: A randomized controlled trial"

1a-ii) Non-web-based components or important co-interventions in title Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support"). subitem not at all important

essential

Clear selection

Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not needed as we only have app-based components.

1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

subitem not at all important

| 1 | \neg |
|---|--------|
| 1 | J |

essential

Clear selection

Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes we mentioned parental outcomes in the title.

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

| subitem not at all important | subitem | not | at | all | important |
|------------------------------|---------|-----|----|-----|-----------|
|------------------------------|---------|-----|----|-----|-----------|

| 1 | |
|---|--|
| 1 | |

|) | |
|---|---|
| _ | 4 |

| 2 | |
|---|--|
| 3 | |

| 1 | |
|---|--|
| t | |

essential

Clear selection

Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The SPA intervention consisted of a mobile application-based psychoeducation and peer support program to support parents from pregnancy till six months



1b-ii) Level of human involvement in the METHODS section of the ABSTRACT Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it) subitem not at all important

essential

Clear selection

Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not an essential piece of information but this was described in the methods section of the main manuscript instead of abstract.

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

| subitem not at all important | |
|------------------------------|-----------------|
| 1 🔘 | |
| 2 | |
| 3 | |
| 4 | |
| 5 🔘 | |
| essential | |
| | Clear selection |

Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

It was stated that participants were "recruited from two public healthcare institutions in Singapore"

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

subitem not at all important

essential

Clear selection

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "Intervention group parents had higher perceived social support than those in the control group at the first (effect size=1.59, 95% CI [0.38, 2.80], Cohen's standardized effect size = 1.31, P=.01), second (effect size=1.98, 95% CI [1.09, 2.88], Cohen's standardized effect size = 2.21, P=.003) and fourth (effect size=2.57, 95% CI [1.62, 3.51], Cohen's standardized effect size = 2.72, P=.048) month postpartum. However, the intervention group parents showed significantly poorer parental bonding (effect size=1.67, 95% CI [0.24, 3.11], Cohen's standardized effect size = 1.16, P=.02). "

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is

| missing from the main body of text, consider adding it) | |
|---|-----------------|
| subitem not at all important | |
| 1 (| |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| essential | |
| | Clear selection |

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Parents in the intervention group generally fared better, especially in terms of perceived social support. However, the lack of statistical significance in most outcomes showed the limited effectiveness of the SPA intervention, which might be due to the COVID-19 pandemic. Parental differences in outcome scores suggest that mothers and fathers have different support needs, thus interventions should be tailored accordingly. Further improvements and evaluations are needed to examine the effectiveness of the SPA intervention in enhancing parental outcomes. Despite statistically insignificant results, the limitations should be considered to further improve mobile-health application-based interventions like SPA, as they could serve as reliable and convenient sources of support for parents."

| П | N٦ | ΓR | \cap | וח | H | \cap | ГΙ | \cap | N | |
|---|----|----|--------|----|----|--------|----|--------|----|--|
| ш | v | ΙП | v | יט | יש | | | v | ıv | |

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

subitem not at all important

essential

Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

studies examining the support needs of parents reported that reliable information on pregnancy and childcare provided by healthcare professionals was desired.3,4 Parents hoped to receive localised information that is tailored to their individual needs and relevant to their settings.3,19 Thus, it is important to develop technology-based interventions that would allow parents to receive accurate information and social support. "

2a-ii) Scientific background, rationale: What is known about the (type of) system Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

| subitem | not: | at all | imno | rtant |
|----------|------|--------|--------|--------|
| Jubillii | HOL | at an | 111100 | ıtarıt |

| 1 | |
|---|---|
| 1 | 1 |

| 2 | |
|---|--|
| _ | |

essential

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"majority of new mothers, regardless of their background, are vulnerable to emotional distress and postnatal depression (PND). Fathers have reported facing emotional distress as well, especially due to confusion in their role and involvement in childcare and pregnancy." and "the market is saturated with a mix of good and bad quality applications that often requires parents to undergo cycles of trial and error to find one that suits them. Virani and colleagues found that while evidence-based apps are scientifically accurate and reliable, they often lack the element of user engagement that draw parents into using them. On the contrary, while commercial parenting apps tend to provide content that are influenced by profits, they have more intuitive user interfaces that make them more popular."

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This study aimed to examine the effectiveness of the SPA intervention on parental outcomes such as PND, anxiety, parental self-efficacy, perceived social support, parental bonding and parental satisfaction across the perinatal period. It was also hypothesised that the intervention group will have significantly lower scores on PND (primary outcome) and anxiety compared to the control group and significantly higher scores for parental selfefficacy, perceived social support, parental bonding and parental satisfaction compared to the control group receiving standard care from baseline to 12 months postpartum."

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The present study adopted a two-groups pre-test and repeated post-test RCT design."; "Couples were allocated to either intervention or standard care using sealed envelopes containing nonduplicated numbers (1-200) to determine their allocation to the 2 groups."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No changes were made to methods after trial commencement.

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A

| description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2]. | |
|---|--|
| subitem not at all important | |
| 1 🔘 | |
| 2 | |
| 3 🔘 | |
| 4 🔘 | |
| 5 | |
| essential | |
| Clear selection | |
| | |
| | |
| Does your paper address subitem 3b-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks | |

No significant changes were made to the app after trial commencement.

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Heterosexual married couples were recruited from two public healthcare institutions in Singapore based on the following inclusion criteria: (1) both parents were 21 years old and above; (2) able to read and speak English; (3) had a low-risk pregnancy with more than 24 weeks of gestation (age of viability in Singapore); (4) owned a smartphone with internet access. Participants were excluded from the RCT if they were diagnosed with physical or mental disorders that would affect their ability to participate, or if they had high-risk pregnancy (e.g. placenta-previa major, pre-eclampsia, pregnancy-induced hypertension). Those who had a complicated assisted delivery, stillbirth, gave birth to a newborn with congenital issues or whose infant was admitted to neonatal intensive care unit (NICU) were also excluded from the study as information provided on the SPA might be misleading or unsuitable for them. "

| 4a-i) Computer / Internet literacy Computer / Internet literacy is often an implicit "de facto" eligibility criteri explicitly clarified. | on - this should be |
|--|---------------------|
| subitem not at all important | |
| 1 🔘 | |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| essential | |
| | Clear selection |

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"able to read and speak English"; "owns a smartphone"

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

subitem not at all important

| 1 | |
|---|--|
| 1 | |

| | _ | - |
|---|-----|---|
| 2 | | 7 |
| _ | _ (| |

essential

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Couples were approached by a research assistant during their routine antenatal check-ups at two public healthcare institutions in Singapore and given a summary of the purpose and details of the study. Interested couples were screened for eligibility and provided their written informed consent."

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

| | subitem | not | at a | all | imi | oor | tant |
|--|---------|-----|------|-----|-----|-----|------|
|--|---------|-----|------|-----|-----|-----|------|

essential

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Couples were approached by a research assistant during their routine antenatal check-ups at two public healthcare institutions in Singapore and given a summary of the purpose and details of the study. Interested couples were screened for eligibility and provided their written informed consent."

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Couples were approached by a research assistant during their routine antenatal check-ups at two public healthcare institutions in Singapore and given a summary of the purpose and details of the study."

| 4b-i) Report if outcomes were (self-)assessed through online question Clearly report if outcomes were (self-)assessed through online questionnair common in web-based trials) or otherwise. | |
|---|-----------------|
| subitem not at all important | |
| 1 (| |
| 2 | |
| 3 🔘 | |
| 4 | |
| 5 | |
| essential | |
| C | Clear selection |

Does your paper address subitem 4b-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The primary outcome (maternal PND) and secondary outcomes (anxiety, parental selfefficacy, perceived social support, parental bonding and parenting satisfaction) were measured using validated self-reported questionnaires. "

4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

| 1 | 1 | | 3 |
|---|-----|---|---|
| | - 1 | C | ע |

| _ | |
|---|---|
| 2 | (|
| _ | |

| 2 | |
|---|--|
| 3 | |

| 4 |) |
|---|---|
| | ı |

| _ | _ | |
|---|---|--|
| 5 | (| |

essential

Clear selection

Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not an important issue in our study as we did not display the institution names on the



5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript). subitem not at all important essential

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have provided some details of our procedure and intervention, but more information has been published on a separate development paper that has been published and cited in this manuscript.

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

subitem not at all important

| _ | | |
|---|-----|-----|
| 1 | - (| - 1 |
| | | J |

| | _ | _ |
|---|---|---|
| 2 | | |
| _ | | 1 |

| 2 | |
|-----|--|
| . 5 | |
| | |

| 1 | |
|---|--|
| 4 | |

| E | - | |
|---|---|--|
| ວ | (| |

essential

Clear selection

Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Well-established theoretical frameworks guided the development of the SPA, such as the mHealth user engagement pyramid by Singh and colleagues, the social cognitive theory founded by Bandura and the attachment theory proposed by Bowlby. These frameworks helped to determine the type of information and the mode in which the information should be delivered to fulfil the informational support needs of parents."

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

subitem not at all important

| 4 | - | ١ |
|---|---|---|
| | (| J |
| | • | , |

| | _ |
|---|---|
| 2 | |
| _ | (|
| _ | |

| | | s |
|---|---|---|
| 2 | | î |
| 3 | (| |
| | | |

| 4 | |
|---|--|
| 7 | |

essential

Clear selection

Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No major changes made to the app.

5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

subitem not at all important

essential

Clear selection

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Healthcare professionals were involved in the development of the app to provide accurate information.

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screencapture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other

| researchers should in principle be able to replicate the study) is a hallmark or reporting. | of scientific |
|---|-----------------|
| subitem not at all important | |
| 1 🔘 | |
| 2 | |
| 3 🔘 | |
| 4 | |
| 5 | |
| essential | |
| | Clear selection |

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please see figure 1 for more information.

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

subitem not at all important

Clear selection

Does your paper address subitem 5-vi?

essential

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please see figure 1 for more information.

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

subitem not at all important

- 1 C
- 2
- 3
- 4
- 5

essential

Clear selection

Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This has been mentioned in the procedure section and also when discussing eligibility criteria.

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and - if computer-mediated communication is a component - whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

| subitem | not at all | important |
|---------|------------|-----------|
| 1 (| \bigcirc | |

essential

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Well-established theoretical frameworks guided the development of the SPA, such as the mHealth user engagement pyramid by Singh and colleagues29, the social cognitive theory founded by Bandura30 and the attachment theory proposed by Bowlby31. These frameworks helped to determine the type of information and the mode in which the information should be delivered to fulfil the informational support needs of parents."; "The SPA included knowledge-based content curated by a multi-disciplinary team of healthcare professionals on pregnancy, childbirth, baby care, maternal care, family, parenthood and mental health to offer parents accurate, relevant and reliable information (see Figure 1). The content was present in various forms such as written articles, audio clips and videos. Discussion forums, frequently asked questions (FAQs) and an expert advice (on daily basis) were also available on the app to resolve any

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

subitem not at all important

- 1 **C**
- 2 C
- 3
- 4
- 5

essential

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"To enhance usage of the SPA, frequent app notifications were sent to the parents to suggest timely resources based on the specific needs and major milestones during their perinatal timeline. Peer volunteers and parents would communicate with one another through the mobile app, or on their preferred messaging platforms."

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

| subitem not at all important | | |
|------------------------------|-----|--|
| 1 | 0 | |
| 2 | • | |
| 3 | 0 | |
| 4 | 0 | |
| 5 | 0 | |
| essent | ial | |

Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants engaged in the app and with peer volunteers as needed, so there are no regular intervals where human involvement is needed.

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

| | subitem | not | at | all | im | por | tan | t |
|--|---------|-----|----|-----|----|-----|-----|---|
|--|---------|-----|----|-----|----|-----|-----|---|

| 1 | |
|---|---|
| 1 | 4 |

essential

Clear selection

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"To enhance usage of the SPA, frequent app notifications were sent to the parents to suggest timely resources based on the specific needs and major milestones during their perinatal timeline. Peer volunteers and parents would communicate with one another through the mobile app, or on their preferred messaging platforms."

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

| 1 | | |
|---|-----|--|
| | - (| |

essential

Clear selection

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The peer volunteers were specially trained to provide peer support"

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The primary outcome (maternal PND) and secondary outcomes (anxiety, parental self-efficacy, perceived social support, parental bonding and parenting satisfaction) were measured using validated self-reported questionnaires. " and section on "outcome measures"

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9]. subitem not at all important

essential

Clear selection

Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

Please refer to section on outcome measures.

6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

| subitem not at all i | important |
|----------------------|-----------|
|----------------------|-----------|

| 1 | - | | 7 |
|---|---|---|---|
| 1 | | L | ע |

| | _ | _ |
|---|-----|---|
| 2 | | |
| _ | _ (| |

essential

Clear selection

Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

Parents were able to use the app as and when they would like.

| 6a-iii) Describe whether, how, and when qualitative feedback from participants was |
|---|
| obtained |
| Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups). |
| subitem not at all important |

- 1
- 2
- 3
- 4
- 5

essential

Clear selection

Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

Qualitative feedback not included in RCT

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No changes

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

subitem not at all important

essential

Clear selection

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Sample size calculation section details this.

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable for this RCT

8a) Method used to generate the random allocation sequence NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Prior to recruitment, a statistician involved in the study developed a randomization list using a permuted block randomization method with the Research Randomizer22 (stratified by hospitals and depression scores - more than or equal to 9 on the Edinburgh Postnatal Depression Scale). Couples were allocated to either intervention or standard care using sealed envelopes containing non-duplicated numbers (1-200) to determine their allocation to the two groups. "

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Prior to recruitment, a statistician involved in the study developed a randomization list using a permuted block randomization method with the Research Randomizer22 (stratified by hospitals and depression scores - more than or equal to 9 on the Edinburgh Postnatal Depression Scale). Couples were allocated to either intervention or standard care using sealed envelopes containing non-duplicated numbers (1-200) to determine their allocation to the two groups."

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Prior to recruitment, a statistician involved in the study developed a randomization list using a permuted block randomization method with the Research Randomizer22 (stratified by hospitals and depression scores - more than or equal to 9 on the Edinburgh Postnatal Depression Scale). Couples were allocated to either intervention or standard care using sealed envelopes containing non-duplicated numbers (1-200) to determine their allocation to the two groups."

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

A statistician was used to generate the sequence, and research assistants were involved in enrollment.

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering cointerventions (if any).

subitem not at all important

| 1 | |
|---|--|
| 1 | |

| 2 | |
|---|--|
| _ | |

essential

Clear selection

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No blinding was needed

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

subitem not at all important

- 1 C
- 2
- 3
- 4
- 5

essential

Clear selection

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Informed consent provided this information to participants.

11b) If relevant, description of the similarity of interventions (this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable to this study.

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"All analyses were performed using the IBM SPSS version 27.040, with the statistical significance set at p<0.05. Descriptive statistics for numerical variables were presented as mean (SD) and n (%) for categorical variables. A mixed model for repeated measures from baseline to 12 months postpartum were used to investigate the time trend and time X intervention interaction of the outcome measures over the study period. Linear mixed model with couple identification as random factor was used to investigate the effect of intervention on the outcome measures of interest. The above analyses were accounted for demographical covariates, including gender, education and household

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and

| simple imputation techniques such as LOCF may also be problematic [4]) | • |
|--|-----------------|
| subitem not at all important | |
| 1 🔘 | |
| 2 🔘 | |
| 3 🔘 | |
| 4 | |
| 5 | |
| essential | |
| | Clear selection |
| | |

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In this study, we used mixed model for repeated measures, which can utilize data from participants even though they have not completed all questionnaires at all time points.

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Methods are same for main outcomes.

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

subitem not at all important

- 1
- 2
- 3
- 4
- 5

essential

Clear selection

Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes under ethical considerations

x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

subitem not at all important

Clear selection

Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Explained under 'procedure'

essential

| | X26-iii) | Safety | and a | security | procedures |
|--|----------|--------|-------|----------|------------|
|--|----------|--------|-------|----------|------------|

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

subitem not at all important

| 1 | |
|---|--|
| • | |

| _ | | |
|---|-----|--|
| 2 | - (| |
| _ | | |

essential

Clear selection

Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

no harm was to be expected from usage of the app.

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A total of 200 couples (N=400) were recruited for the study and randomly assigned to the control (n=200) and intervention (n=200) groups. The demographic characteristics of all the participants are presented in Table 1. "

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram)

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please see table 2 and discussion section for reasons.

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

subitem not at all important

| | - | | ١ |
|---|-----|---|----|
| 1 | - (| (|)) |
| | - 1 | _ | 7 |

essential

Clear selection

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have already provided table 2 for attrition.

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This was provided in the methods section.

14a-i) Indicate if critical "secular events" fell into the study period

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

subitem not at all important

| 1 | |
|---|--|
| | |

| 2 | |
|---|---|
| _ | (|
| | |

essential

Clear selection

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No secular events were involved.

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Trial proceeded as intended.

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please see table 1.

| 15-i) Report demographics associated with digital divide issues |
|--|
| In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known. |
| subitem not at all important |
| 1 🔘 |
| 2 🔘 |
| 3 🔘 |
| 4 |

essential

Clear selection

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please see table 1.

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and

| lear selection |
|----------------|
| lear selection |

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please see table 1 and 2.

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

subitem not at all important

essential

Clear selection

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Main outcomes were detailed in the results section.

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please see main and subgroup analysis sections.

17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

subitem not at all important

- 1 (
- 2 **C**
- 3
- 4
- 5

essential

Clear selection

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Some information on the number of views of the articles in the app is provided in the discussion.

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please refer to the results section and tables 3 and 4.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please refer to the results section and tables 3 and 4.

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

| subitem not at al | ll important |
|-------------------|--------------|
| | |

essential

Clear selection

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please see section under subgroup analyses.

19) All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No harm is expected to occur from using the app.

19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

subitem not at all important

| 4 | | |
|---|-----|---|
| 1 | - (| |
| • | _ | _ |

| _ | | - |
|---|-----|---|
| つ | - (| |
| _ | _ \ | |

essential

Clear selection

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants used coded usernames when using the app to ensure anonymity.

| 19-ii) Include qualitative feedback from | participants or | observations | from |
|--|-----------------|--------------|------|
| staff/researchers | | | |

Include qualitative feedback from participants or observations from staff/researchers, if

| available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers. |
|---|
| subitem not at all important |
| 1 |
| 2 🔘 |
| 3 🔘 |
| 4 |
| 5 |
| essential |
| Clear selection |
| Does your paper address subitem 19-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Qualitative feedback have been provided in a separate publication. |
| DISCUSSION |

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

| subitem | not | at | all | im | nο | rta | nt |
|-----------|-----|----|-----|------|----|-----|-----|
| SUDILEIII | HΟL | aι | all | 1111 | μυ | ıιa | 110 |

| 1 | |
|---|--|
| 1 | |

| _ | |
|---|---|
| ソ | (|
| _ | |

essential

Clear selection

Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please see the discussion section.

| 22-ii) Highlight unanswered new questions, suggest future research. | :h |
|---|-----------------|
| subitem not at all important | |
| 1 (| |
| 2 | |
| 3 🔘 | |
| 4 | |
| 5 | |
| essential | |
| | Clear selection |

Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please see the discussion section. "However, further research is needed to confirm the specific types of support appreciated by the parents and to evaluate the effectiveness of peer support for fathers provided by other similar fathers."

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

| subitem | not a | it all i | mpor | tant |
|---------|-------|----------|------|------|
| | | | | |

essential

Clear selection

Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Despite the ample size of the sample recruited, there was still an overall attrition rate of 28.5%, which was higher than the 20% initially postulated. The long follow-up duration (up to 12 months postpartum) and the outbreak of COVID-19 might have caused this high attrition rate. Another reason for this attrition rate could also be the parents' disengagement with the SPA intervention. However, the present study did not obtain sufficient data on the SPA user engagement to distinguish between the two causes of the attrition rate. Recent literature57 has emphasised the importance of investigating user engagement in mHealth apps to provide a better understanding of user experiences and maintain or increase the users' activity on these apps. Thus, it is important for future studies on mHealth apps to develop extensive plans around how to investigate and build user engagement. Based on our experiences, future studies can build better rapport with the participants by checking in with parents more regularly, sending encouraging messages and reminding parents to use the SPA for their parenting and pregnancy related concerns. Closer communication between research team and peer volunteers can also be facilitated in order to provide more specialised support suited to the needs of the parents so that the intervention can be more engaging for the parents.

Another limitation of this study was that due to human error, there was no information on whether the parents recruited were new or experienced. This is a major limitation as the experiences, struggles and support needs of new and experienced parents can differ widely. It is important for future studies to include this information to provide greater depth in understanding how the intervention impacts the differing needs of these parents. Such human errors had occurred mainly because majority of the study team members were clinicians who had to devote their attention to supporting parents in clinical settings during the pandemic. Hence, the lack of regular meetings between team members led to increased incidence of human errors and compromised communication.

No data on the parents' use of other parenting apps were collected. This was also a limitation of the present study, as the usage of these other mobile apps could have provided greater insight into the interpretation of our results. Furthermore, we believe that due to the hectic duties juggled by parents, they might forget to access the SPA for information or advice from experts and peer volunteers despite regular notifications. As the SPA was only programmed to send regular notifications depending on the stage of pregnancy or age of the newborn, some parents might have accidently switched off receiving those notifications or those who received could have been preoccupied to settle other pressing demands around parenting during the evolving COVID-19 related restrictions. It was also possible that the notifications were not received if parents did not update the SPA when prompted to. Thus, more frequent robust ways of reaching out to parents beyond regular notifications may be needed so that parents would visit the app more actively to maximise the benefits they can reap from the SPA intervention."

21) Generalisability (external validity, applicability) of the trial findings NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

subitem not at all important

- 1 (
- 2 C
- 3
- 4
- 5

essential

Clear selection

Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Attrition rate may affect generalizability of findings.

| 21-ii) | Discuss if there | were elements | in the RCT | that would b | oe different ir | n a routine |
|--------|------------------|---------------|------------|--------------|-----------------|-------------|
| applic | cation setting | | | | | |

Discuss if there were elements in the RCT that would be different in a routine application catting (a.g. prompte/reminders more human involvement training sessions or other co

| interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting. | | |
|---|---|--|
| subitem | not at all important | |
| 1 | 0 | |
| 2 | | |
| 3 | 0 | |
| 4 | 0 | |
| 5 | 0 | |
| essentia | | |
| | Clear selection | |
| | | |
| Copy and "like this' providing applicable | ur paper address subitem 21-ii? If paste relevant sections from the manuscript (include quotes in quotation marks to indicate direct quotes from your manuscript), or elaborate on this item by additional information not in the ms, or briefly explain why the item is not le/relevant for your study | |
| Copy and "like this' providing applicable Not that | d paste relevant sections from the manuscript (include quotes in quotation marks to indicate direct quotes from your manuscript), or elaborate on this item by additional information not in the ms, or briefly explain why the item is not le/relevant for your study | |

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. Ethics approval was obtained from the National Health Group Domain Specific Review Board (NHG DSRB: 2019/00875).

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Ethics approval was obtained from the National Health Group Domain Specific Review Board (NHG DSRB: 2019/00875).

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This work was supported by the Ministry of Health [HSRGHP18may-0001].

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated

| subitem not at all important 1 | |
|--|----------------|
| | |
| 2 🔘 | |
| | |
| 3 | |
| 4 | |
| 5 | |
| essential | |
| C | lear selection |
| | |
| | |
| Does your paper address subitem X27-i? Copy and paste relevant sections from the manuscript (include quotes in qu | |
| C | lear selection |

No conflict of interest v

About the CONSORT EHEALTH checklist

| As a result of using this checklist, did you make changes in your manuscript? * | | | |
|--|--|--|--|
| yes, major changes | | | |
| yes, minor changes | | | |
| o no | | | |
| | | | |
| What were the most important changes you made as a result of using this checklist? | | | |
| Your answer | | | |
| How much time did you spend on going through the checklist INCLUDING making * | | | |
| changes in your manuscript | | | |
| 30 minutes | | | |
| | | | |
| As a result of using this checklist, do you think your manuscript has improved? * | | | |
| O yes | | | |
| o no | | | |
| Other: | | | |

| 11 PM | CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form |
|-----------------------|---|
| | |
| Would you like to | become involved in the CONSORT EHEALTH group? |
| | e for example becoming involved in participating in a workshop and ation and Elaboration" document |
| O yes | |
| o no | |
| Other: | |
| | Clear selection |
| | |
| Any other comm | ents or questions on CONSORT EHEALTH |
| Your answer | |
| | |
| STOP - Save this | form as PDF before you click submit |
| To generate a reco | ord that you filled in this form, we recommend to generate a PDF of this imply select "print" and then select "print as PDF") before you submit it. |
| When you submit file. | your (revised) paper to JMIR, please upload the PDF as supplementary |

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit!

Click submit so we have your answers in our database!

Submit Clear form

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy

Google Forms